Traduction de «come from another country which » (Néerlandais → Français) :

If you come from another country which does not issue EHICs, you may register as a “resident” if you hold a residence permit that is valid for this type of registration.
If you come from another country which does not issue EHICs, you may register as a « resident » if you hold a residence permit that is valid for this type of registration.

Indeed, this would require the explaining of a whole series of paradoxical empirical results: the suicide rate varies considerably from one country to another; it is subjected to long-term fluctuations in some countries, but remains remarkably stable when compared to other countries; in times of war the rate goes down, etc.
Il faudrait expliquer toute une série de résultats empiriques paradoxaux: le taux de suicides varie beaucoup à l’échelle des nations; il est soumis à des fluctuations sur le long terme dans certains pays, mais comparé à d’autres pays, il reste étonnamment stable; en période de guerre le taux baisse, etc.

The seriousness of the situation, the differences in regulations from country to country, the difficulty of determining at the start of an incident whether it is a quality problem or a problem of pharmacovigilance, are factors which have to be taken into account.
The seriousness of the situation, the differences in regulations from country to country, the difficulty of determining at the start of an incident whether it is a quality problem or a problem of pharmacovigilance, are factors which have to be taken into account.

Novartis will launch an OTC version of pantoprazole, another proton pump inhibitor, in 14 European countries in the second quarter of 2010 after gaining rights from Nycomed.
Novartis lancera, au cours du deuxième trimestre 2010, dans quatorze pays européens une version en vente libre de pantoprazole, un autre inhibiteur de la pompe à protons dont il a obtenu les droits de Nycomed.

Zometa (USD 378 million, +6% cc) expansion has come from improved compliance and increased use of this intravenous bisphosphonate therapy in patients with certain types of cancer which have spread to the bone.
Zometa (USD 378 millions, +6% tcc), progresse grâce à une amélioration de sa conformité et à une augmentation de l’utilisation de ce traitement intraveineux au bisphosphonate contre certains types de cancers provoquant des métastases osseuses.

Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated. In addition to these 74 indicators, 11 indicators for which data are expected
Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated.

Diovan (USD 2.9 billion, +6% lc) benefited from double-digit growth in Japan, which now accounts for about 20% of net sales, and a solid performance in Europe ahead of the anticipated entry of generic versions as early as the second half of 2009 of losartan, another medicine in the angiotensin receptor blockers (ARB) segment.
Diovan (USD 2,9 milliards, +6% en m. l.), a bénéficié d’une croissance à deux chiffres au Japon, qui représente actuellement quelque 20% du chiffre d’affaires net, et d’une robuste performance en Europe. On s’attend à ce que des versions génériques de losartan, un autre médicament du segment des antagonistes des récepteurs de l’angiotensine (ARA), fassent leur apparition au second semestre 2009 déjà.

Zometa (USD 363 million, -3% cc) volume expansion offset by negative EU and Japanese pricing, continued to come from improved compliance and increased use of this intravenous bisphosphonate therapy in patients with certain types of cancer which have spread to the bone.
Zometa (USD 363 millions, -3% tcc), expansion en volume contrebalancée par une fixation défavorable des prix par l’UE et le Japon, progresse grâce à une amélioration de sa conformité et à une augmentation de l’utilisation de ce traitement intraveineux au bisphosphonate contre certains types de cancers provoquant des métastases osseuses.

Results of a one-year study, which was undertaken in response to “approvable letters” from the FDA, achieved primary efficacy and renal function targets and were also consistent with experience seen in 70 countries – including in Europe – where this medicine has been approved.
Les résultats d’une étude d’un an, entreprise en réponse à des «approvable letters» émises par la FDA, a atteints ses objectifs principaux en termes d’efficacité et de fonction rénale. Ces résultats étaient également en adéquation avec les expériences récoltées dans 70 pays – notamment en Europe – où ce médicament est autorisé.

The aim has been to ensure the FAMHP’s continued ability to remain at the forefront of European countries for those aspects for which electronic submission becomes obligatory from 2009.
The aim has been to ensure the FAMHP’s continued ability to remain at the forefront of European countries for those aspects for which electronic submission becomes obligatory from 2009.